Spectrum Pharmaceuticals, Inc. Out-Licenses Rights For Greater China To CASI Pharmaceuticals For Three Of Its Drugs

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HENDERSON, Nev. & ROCKVILLE, Md.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, and CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a primary focus on China, announce the signing of license agreements whereby CASI has been granted exclusive rights to two of Spectrum Pharmaceuticals’ commercial oncology drugs, Zevalin® (ibritumomab tiuxetan) Injection for intravenous use and Marqibo® (vinCRIStine sulfate LIPOSOME injection) for intravenous infusion, and a Phase 3 drug candidate, Captisol-Enabled™ Melphalan (CE melphalan), for development and commercialization in China, including Taiwan, Hong Kong and Macau.

Help employers find you! Check out all the jobs and post your resume.

Back to news